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7 Menstrual disorders in the adolescent female 
Donald E. Creydanus, Shawn Sorrel, and Hatim A. Omar 
·s chapter reviews basic concepts .of menstrual disorders in adolescents beginning 
an overview of menstrual physiology followed by consideration of various abnor-
menstrual patterns: amenorrhea (primary and secondary), dysfunctional uterine 
ng, dysmenorrhea (primary and secondary), and premenstrual syndrome. 
he, or the onset of menstruation, occurs on average at 12.7 years of age in 
can females (approximately 12.16 years in African American females vs. 12.88 
in Caucasian females) (1 ). A responsive H-P-0 (hypothalamic-pituitary-ovarian) 
s induces cyclical menstruation that is regulated by levels of estrogen and progester-
e and results in three classic menstrual phases: follicular, ovulatory, and luteal (2-4). 
lation of the onset and regularity of menses is under many influences, as listed in 
following box (4). The level of exercise in adolescents involved in sports play can 
considerable influence on their menstrual patterns (5) . 
. 1.1 Adolescent menstrual patterns 
menstrual pattern of a mature female adult has a mean interval of 28 days (±7 days) 
a median blood loss of 30 ml per month, with 60-80 cc per month often set as 
r limits of normal blood loss (6). There is more variability in the adolescent female, 
due to lack of regular ovulation for several months to several years after men-
e. Approximately half of her cycles are anovulatory in the first 2 years after 
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menarche, and 20 percent are still without ovulation by the fifth menstrual year. 
median cycle length for adolescent females is 31 days in the first 2 years after men 
arche, in contrast to 28 days for the adult female. Approximately 38 percent of 
at 2 years after menarche are less than 40 days. This classic lack of ovulation in the 
lescent female may result in oligomenorrhea, amenorrhea, or dysfunctional uteri 
bleeding (DUB). Definitions of menstrual abnormalities are noted in ll> Tab. 17.1 
Menstrual disorders discussed below include amenorrhea, DUB, and dysmenorrhea. 
17.2 Amenorrhea 
The absence of menses is called amenorrhea and is defined as primary or 
amenorrhea (7,8,9). The definition of primary amenorrhea is the absence of menstru 
tion by 14 years of age with a sexually maturity rating (SMR) of 1 or by 16 years of 
at a SMR of 2 or greater. Once menses has started, the lack of periods for three cycles 
for 6 months defines secondary amenorrhea. Oligomenorrhea refers to i 
irregular menstrual bleeding over 45-day cycles. Although amenorrhea can be 
in the adolescent for 3 to 6 months for the first 2 years after menarche, a number 
medical conditions can be the cause for an adolescent presenting with amenorrhea (p 
mary or secondary) or oligomenorrhea (see ll> Tabs. 17.2 and 17.3). ll> Tabs. 17.2 
17.4 and the box "Methods to Evaluate Hypoestrogenemia in Adolescents," list va 
laboratory tests useful in this clinical evaluation. The most common cause of 
amenorrhea is pregnancy. Once pregnancy has been ruled out, laboratory testing 
eliminate or confirm hyothyroidism and hyperprolactinemia as potential diagnoses. 
helpful to consider the remaining causes of secondary amenorrhea classified as 
gonadotropic amenorrhea, hypogonadotropic hypogonadism, and m"'"'"'''"n'n"'""'rrn1n1 
Tab. 17.1: Menstrual disorders definitions. 
1. Normal adult menstrual cycle: 
a. Mean interval of 28 days (±7 days) 
b. Duration of menses of 4 days (±2-3 days) 
c. Median blood loss is about 30 ml per month (with the upper limit of normal defined as 
80 ml per month). 
2. Amenorrhea: Absence of menses; can be primary or secondary (absence of three 
menstrual cycles, after regular periods have been established) 
3. Oligomenorrhea: Infrequent, irregular bleeding at >45-day intervals 
4. Menorrhagia: Prolonged (>7 days) or excessive (>80 ml) uterine bleeding occurring at 
intervals 
5. Metrorrhagia: Uterine bleeding occurring at irregular but frequent intervals, the amount 
variable 
6. Menometrorrhagia: Prolonged uterine bleeding occurring at irregular intervals 
7. Hypermenorrhea: Synonymous with menorrhagia 
8. Polymenorrhea: Uterine bleeding occurring at regular intervals of <21 days 
9. DUB: abnormal (different from that patient's normal) uterine bleeding that is unrelated to 
anatomic lesion 
Reprinted, with permission, from (1, p. 547). 
Gynecologic Disorder 
Amenorrhea (primary) 
Amenorrhea 
(secondary) 
Dysmenorrhea 
(primary) 
Dysmenorrhea 
(secondary) 
Special Comments 
Physiological is the main cause; Mayer-
Rokitansky-Kuster-Hauser (MRKH) 
syndrome assoc. with renal abnormalities 
and spinal malformations. Short stature 
with delayed sexual maturation: Turner 
syndrome; delayed sexual maturation + 
hypertension seen in 17 -a-hydroxylase 
deficiency; Swyer syndrome; absence of 
smell sense suggests Kallmann syndrome; 
visual field deficits suggest brain tumor. 
Pregnancy is the main cause: history of 
sexual activity - may present wi th a 
midline "pelvic mass"; causes of 
oligomenorrhea and secondary 
amenorrhea are essentially the same. 
Also important is history of dietary habits, 
exercise, stress; acne and hirsutism 
suggest elevated androgen levels; 
Athlete Triad Syndrome: amenorrhea, 
dysfunctional eating patterns, osteopenia-
porosis. 
Pelvic pain during normal ovulatory 
menstruation; no underlying pelvic 
pathology. May also see gastrointestinal 
symptoms, headache, myalgia, sweating. 
May be seen at menarche or 3+ years 
postmenarche. 
Differential Diagnosis 
Physiological Imperforate hymen 
MRKH syndrome; Turner syndrome 
(45, XO and mosaicism) Chronic 
Illness Hypothalamic: Stress, eating 
disorders, exercise, depression; 
Androgen insensitivity syndrome (46 
XY); Swyer syndrome; others: see 
section 17.2 
Pregnancy; lactation; 
Stress, eating disorders, 
Chronic illness, 
Exercise-induced, 
prolactinoma (headaches, visual field 
deficits, galactorrhea) 
PCOS; 
See section 17.2 .3 . 
Physiological 
Endometriosis 
Pelvic Inflammatory Disease (PID) 
Reproductive tract anomalies 
Pelvic adhesions 
Cervical stenosis 
Laboratory Testing 
Serum gonadotropins (follicle stimulating 
hormone [FSH], luteinizing hormone 
[LH]), prolactin, thyroid stimulating 
hormone; Pelvic Ultrasound MRI, Head 
CT/MRI Renal ultrasound/intravenous 
pyelogram (IVP); karyotype laparoscopy 
Pregnancy 
Test (~-hCG) 
Progesterone challenge 
Serum estrogen, FSH, LH; 
bone mineral densitometry; 
Serum prolactin 
Thyroid screen; 
Head CT 
Laparoscopy 
STD screen 
Pelvic Ultrasound; MRI 
(Continued ) 
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Tab. 17.2: Gynecologic disorders of adolescent females. (Continued) 
Gynecologic Disorder Special Comments Differential Diagnosis 
DUB 
Ectopic pregnancy 
Endometriosis 
Mittelschmertz 
Ovarian masses 
Menstrual calendar useful to get accurate 
history of menstrual pattern; get sexual 
activity history; 
Establish presence/absence of ovulation: 
basal body temperature charts, serum 
progesterone, urinary LH and possibly 
endometrial biopsy. 
rule out an STD; virilization evaluation 
necessary if hirsutism present. 
Pain with history of secondary 
amenorrhea, often with vaginal bleeding. 
Ovarian masses 
Pelvic congestion syndrome 
Rule out Urinary Tract or 
Gastrointestinal causes 
Anovulatory bleeding; 
Pregnancy, ectopic pregnancy; 
coagulation disorders (as von 
Willebrand disease, others), anatomic 
lesions, endometrial pathology; 
cervicitis or cervical dysplasia; PID; 
ovarian cysts; polycystic ovary 
syndrome; severe stress, rapid or 
severe weight gain or loss, drug abuse; 
see text. 
See DUB differential 
Presentation in adolescence not the same See secondary dysmenorrheal 
as in adults. May have acyclic pain, 
abnormal uterine bleeding, Gl 
symptomatology 
Pain associated with ovulation in the See secondary dysmenorrhea 
middle of a menstrual cycle. May last 1-3 
days and be mild to severe. 
Presents with a lateral location; abnormal Ovarian cysts 
menses Ovarian tumors (benign, malignant) 
Polycystic ovary syndrome 
Ectopic Pregnancy 
Tubo-ovarian mass 
Laboratory Testing 
CBC, platelets, beta-HCG, Pap smear, PT, 
PTT, bleeding time, other coagulation 
disorders screening; D-21 progesterone; 
thyroid screen; STD screen; ultrasound 
(transvaginal; pelvic), MRI; hysteroscopy. 
~-hCG; pelvic ultrasound 
Laparoscopy 
Laparotomy 
Menstrual calendar 
Pregnancy test 
Pelvic Ultrasound 
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Pelvic inflammatory 
disease (PID) 
PCOS; 
hyperandrogenemia 
syndrome 
STD that can lead to uterine tenderness, 
adnexal tenderness, tenderness on cervical 
motion, muco-purulent vaginal or cervical 
discharge; can see fever (T > 101 F, 38 .3 
C); polymicrobial disorder of the upper 
genital tract often precipitated by Neisseria 
gonorrhoeaeCh/amydia trachomatis, 
others (Cardnerella vagina/isMycoplasma 
hominisUreaplasma 
urealyticumHaemophilus influenzae, 
coliforms, cytomegalovirus, 
peptostreptococcus, and other anaerobes). 
Can involve various combinations of 
endometritis, salpingitis, tubo-ovarian 
abscess, and pelvic peritonitis. 
Complications include infertility, chronic 
pelvic pain, ectopic pregnancy. 
Insul in resistance w ith hyperinsulinemia, 
hyperandrogenemia, and chronic 
anovulation; can see irregular menses 
(secondary amenorrhea, oligomenorrhea, 
DUB), hirsutism, possible virilization, 
variable obesity, acanthosis nigricans, 
possible bilateral enlarged ovaries. 
Ectopic pregnancy, appendicitis, 
pyelonephritis, ovarian cyst, septic 
abortion, others. 
Other causes of hyperandrogenism; 
HAIR-AN Syndrome; Congenital 
adrenal hyperplasia (11 IS-hydroxylase, 
21-hydroxylase, 3 IS-hydroxysteroid 
dehydrogenase deficiency); Cushing's 
disease, hyperprolactinemia; Ovarian 
or adrenal tumor; Mixed gonadal 
dysgenesis (45X/46XY, 45X/46XX/ 
46XY); Gonadal dysgensis with 
virilization; true hermaphroditism 
Nonspecific: 
White blood cells on saline prep; elevated 
ESR; elevated CRP; lab evidence of 
Neisseria gonorrhoeae or Chlamydia 
trachomatis; 
Specific Criteria 
Positive biopsy: Endometrium showing 
endometritis; Evidence of PID on 
laparoscopy; ultrasound or MRI showing 
that fallopian tubes are thick and filled 
with fluid; may be free flu id in the pelvis 
or a tuba-ovarian complex. 
LH, FSH, T-4, prolactin, testosterone (total 
and free), insulin level; lipid profile; 
dehydroepiandrosterone sulfate (DHEAS); 
17-a-hydroxyprogesterone; 24 hour urine 
for free cortisol; dexamethasone 
suppression test; Pelvic ultrasound 
(Con tinued) 
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Tab. 17.2: Gynecologic disorders of adolescent females. (Contin ued) 
Gynecologic Disorder Special Comments Differential Diagnosis 
Premenstrual 
syndrome (PMS) 
Variety of symptoms start before and end 
w ith menses 
Premenstrual dysphoric disorder 
(PMDD); depression; anxiety; others, 
depending on the presenting 
symptoms; see text. 
Laboratory Testing 
DSM-/V (2000) criteria for PMDD 
Abbreviations: CBC: complete blood count; Pap: Papanico laou smear; STD: sexually transmitted disease; MRI: magnetic resonance imaging; Gl: 
gastrointestinal; ESR: erythrocyte sedimentation rate; F; Fahrenheit; C: Centigrade; HAIR-AN: hyperandrogenism, hirsutism, insulin resistance, 
acanthosis nigricans; DSM- IVDiagnostic and Statistical Manual, 4th edn (American Psychiatr ic Association); PT: prothrombin time; PTT: partial 
thromboplastin time. *Reprinted with permission from Greydanus DE, Feinberg AR, Patel DR, Homnick ON, eds. The pediatric diagnostic 
exam ination. New York: McGraw-H ill, 2008. 
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17.2 Amenorrhea j 307 
17.3: Clinical classification of amenorrhea in the adolescent. 
Primary Amenorrhea with Puberta l (Sex) Delay 
A. Gonadal malformation 
1. Turner syndrome (gonadal dysgenesis) 
2. Testicular feminization syndrome (androgen insensiti vity syndrome) 
B. Hypothalamic-pituitary dysfunction 
1. Physiological delay (most common) 
2. Functional disorders: hypothalamic-induced: such as weight loss, eating disorders, 
exercise, stress, others 
3. Organic disorders: prolactinoma, chronic illness, others 
Primary Amenorrhea without Pubertal (Sex) Delay 
A. Pseudoamenorrhea 
1. Imperforate hymen 
2. Transverse vaginal septum 
B. MRKH syndrome (agenesis of vagina, cervix, uterus) 
C. PCOS (hyperandrogenemia syndromes) 
D. Chronic illness (including thyroid disorders) 
E. Others 
Secondary Amenorrhea 
1 . Pregnancy (most common) 
2. Hypothalamic-induced: such as weight loss, eating disorders, exercise, stress 
3. PCOS (hyperandrogenemia syndromes) 
4. Thyroid disorders 
5. Pituitary disorders (pituitary adenoma) 
6. Hypoestrogenemia (ovarian dysfunction or ovarian hypofunction) 
7. Chronic illness 
8. Others 
and reprinted with permission from (12). 
test 
investi gation: 
LH & FSH : Increased in ovarian failure/dysgenesis; normal or decreased in others 
Thyroid hormone levels 
Pro lactin levels 
If virilization/hirsutism present: DHEAS, LH/FSH ratio (n1 :<2.5:1), testosterone (total and free) 
Level of estradiol & progesterone and/or 
Vaginal smear to evaluate for epithelial cell estrogenization 
Pelvic ultrasound to define anatomy (uterus hypoplas ia) 
Vaginoscopy 
Chromosome evaluation 
(Continued) 
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Tab. 17.4: Laboratory testing for amenorrhea in adolescents. (Continued) 
Antiovarian antibodies 
Head CT/MRI 
Pelvic/abdominal MRI 
Renal ultrasound/IVP 
Laparoscopy 
hypogonadism, each having specific etiology. The most common causes of normogon,adiJ-YN 
tropic amennorhea are outflow obstruction and hyperandrogenic chronic 
Polycystic ovarian syndrome (PCOS) is the most common cause of m"""''""nrm-.mm 
chronic anovulation. The high prevalence of secondary amenorrhea seen in 
athletes warrants further discussion. 
17.2.1 Amenorrhea in adolescent athletes 
Amenorrhea and oligomenorrhea are commonly encountered in the adolescent 
population (1 0,11 ). Menarche may be delayed in an adolescent athlete five 
for each year of intense, prepubertal exercise. Furthermore, secondary amenorrhea 
well-described in female athletes participating in cycling, gymnastics, and 
sports. Menstrual dysfunction is noted in 12 percent of swimmers as well as 
44 percent of ballet dancers, 50 percent of female triathletes, 51 percent of 
runners, and up to 20 percent of strenuously exercising females in general 
Research suggests that up to 15 percent of all female athletes and two-thirds of el 
female athletes have menstrual dysfunction. 
As noted in the previous box ,"Influences on the Menstrual Cycle," there are 
factors influencing menstruation in adolescent athletes . ..,.. Tabs. 17.2 and 1 7.3 
the etiology of amenorrhea. The most common cause of amenorrhea in 
involved with intense exercise is hypogonadotropic hypogonadism in which 
is dysfunction of the GnRH production and LH pulsativity. Low body fat, 
is a factor, is not the sole reason for menstrual dysfunction. The role of leptin 
the complex menstrual process is not yet clear. Previous theories implying that 
struation cannot occur below a body fat percentage of 1 7 percent are not proved (1 
Low body weight by itself does not cause amenorrhea and the weight of a female 
lete with no menses can be the same or even more than one with a normal 
pattern. 
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The intense exercise pattern induces such a major energy drain that the caloric intake 
this athlete is not sufficient to maintain normal menstrual function. Meeting the 
nergy needs of the athlete is the cornerstone to restoring normal menstrual function. 
is treatment is further discussed. 
7 .2.2 Management of amenorrhea 
management of an adolescent female with amenorrhea or oligomenorrhea is 
rmined by the underlying cause(s) of the menstrual dysfunction. If intense exercise 
is a central theme, the clinician can recommend a reduction in exercise by 
0 percent or more. Typically in the female athlete triad (i.e. irregular menses as amen-
disordered eating, and osteopenia -osteoporosis) (4), eating patterns may be 
normal as well, and she should be advised to improve her nutritional intake, includ-
ng taking calcium and vitamin D supplementation. Consultation with a sports nutri-
. ist can help the patient ensure she is meeting the nutritional and ca loric needs 
fically during involvement in sports. If menstrual dysfunction is part of a chronic 
h\ tnr,oc·~rnno•no•""'ia (see the previous box, "Methods to Evaluate Hypoestrogenemia in 
lescents"), she is at increased risk for reduced bone mineral density, osteopenia 
eventually osteoporosis. Females with chronic lack of menstruation and low 
mineral density (BMD) may never acquire a normal BMD even if the menstrual 
eventually is normalized. 
Female athletes with low BMD are increased risk for the development of stress 
fractures. Daily supplementation with calcium (1 ,000-1,500 mg per day), vitamin D 
IU per day), vitamin 8 complex, and vitamin E (1 00- 200 IU per day) is 
' rl'•rnmnnor,red for this athlete with menstrual dysfunction and/or eating dysfunction (1 0). 
imately 50 percent of bone mass is acquired during the adolescent years, and 
us, if the female adolescent athlete has a low BMD, estrogen supplementation (conju-
estrogen or oral contraceptives) is suggested by many clinicians in an attempt to 
her prevent bone loss. 
The American Academy of Pediatrics has recommended that the amenorrheic ado-
athlete not be given hormonal medication if she is within three years of 
he; instead, she should be advised to lower her exercise pattern intensity and 
her nutritional intake (including adequate calcium intake) (13). Estrogen supple-
ntation (typically the oral contraceptive) is recommended for the amenorrheic 
Jete if she is over 3 years from menarche and over age 16; hormonal management 
used for those under age 16 years, if there is a history of a stress fracture. 
However, problems in the management of these athletes often arise. For example, 
any committed athletes will not lower their intense exercise patterns nor alter their 
healthy dietary habits. Also, estrogen supplementation is controversial and not 
n to enhance or protect BMD, with or without weight gain. It is not currently 
n what the actual acute or chronic implications are of chronic amenorrhea and 
ial estrogen deficiency in the female adolescent athlete or in other females 
th these issues. 
The use of conjugated estrogen or the oral contraceptive does not correct the under-
·ng menstrual dysfunction and after the estrogen is stopped, the abnormal menstrual 
often resumes. There are a number of potential side effects to oral contracep-
ves, including breast tenderness, breast congestion, nausea, emesis, weight gain, 
31 0 I 17 Menstrual disorders in the adolescent female 
and others. Some studies suggest that oral contraceptives under 50 meg estrogen 
not be helpful in preventing osteoporosis (4). BMD is usually the most reduced in 
who are thin and not active. Intense exercise involving weight bearing leads to 
mechanical forces neutralizing the low BMD effect of a thin body type; bone 
may be enhanced by weight-bearing exercise, allowing some amenorrheic athletes 
tennis players, ice skaters, runners, gymnasts) to have normal or increased BMD. 
17.2.3 Management of PCOS 
PCOS is characterized by hyperandrogenism and chronic oligo-ovulation 
clinical presentation is heterogenous and often difficult to recognize in 
due to the coinciding signs and symptom of puberty including increased 
production . ~Tab. 17.2 provides key features as well as a differential diagnosis, 
suggested laboratory evaluation. ~Tab . 17.5 lists laboratory results which may 
found in PCOS and support the diagnosis. ~Tab. 17.6 lists potential 
options for adolescent females with PCOS. Treatment of PCOS is multifactorial and 
eludes addressing obesity if present, decreasing androgen levels, and improving 
resistance. 
Oral contraceptive pills (OCPs) are the mainstay of treatment in PCOS. 
decrease LH secretion and thus decrease ovarian androgen secretion, protect the 
metrium from unopposed estrogen stimulation, and increase sex hormone 
Tab. 17.5: Laboratory test results in PCOS patients. 
Hyperinsulinemia (fasting levels of glucose/ insulin ratio <4.5) 
LH: Mild T 
FSH: Low limits of normal 
LH-FSH ratio: >2.5:1 
Estradiol: Moderate T 
17-hydroxyprogesterone: mild T 
Androgen: mild to moderate T in levels 
e free and total testosterone 
• early morning urinary 17-ketosteroids 
• androstenedione 
• DHEAS (can also be normal) 
Sex hormone-binding globulin: 1 
Prolactin : Mild T 
Abnormal lipid profile 
• 1 high-density lipoprotein 
• T cholesterol 
• T very-low density lipoprotein 
• T low-density lipoprotein 
• T triglycerides 
Tab. 17.6: Management options for PCOS pati ents. 
Combined oral contraceptives (COCs) 
Transdermal (patch) contraption 
Transvaginal hormonal contraceptives (NuvaRing) 
Progesterone 
Spironolactone (androgen receptor antagonist) (hirsutism) 
Flutamide (androgen receptor antagonist) (hirsutism) 
Metformin 
Management of obes ity 
Management of acne vulgaris 
Hair removal (electrolys is and thermolysis) 
Ovulation induction (usually only for adults) 
• Clomiphene citrate 
• GnRH agon istic analogs (leuprolide acetate or nafarelin) 
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Laser "drilling" of the ovary (1 ovarian stromal steroids by reducing the stroma) 
Management of potential comorbid endocrinopathies 
globulin whi ch then decreases free testosterone to improve hirsutism and acne. No spe-
cific ocp has shown to be more effective; however, Yasmin which contains both ethinyl 
estradiol and drosperinone decreases both ovarian and adrenal androgen secretion. 
Medroxyprogesterone (Provera - 10 mg) or micronized progesterone (Prometrium) can 
I so be prescribed to induce withdrawal bleeding if this is taken orally for 12-14 days 
each month. 
The treatment of hirsutism can include shaving, bleaching, depilatories and electroi-
Pharmacological treatment includes eflornithine (Vaniqua) which is an approved 
cream that acts as a hair growth retardant. Androgen receptor antagonists (such 
spironolactone [50 to 100 mg twice a day]) or anti androgens (such as flutamide or 
cnt.ocrmo acetate), although they are not approved for the treatment of hirsutism, 
commonly used. Metformin (Giucophage) can be used to lower serum insulin levels 
with reducing ovarian cytochrome P450c17a activity and improving hyperandro-
found in obese PCOS adolescent females. Pl ease refer to the endocrine chapter 
2) for treatment of diabetes mellitus. Early intervention with androgen suppres-
therapy along with exercise and proper nutrition can improve the lives of these 
in their future adulthood periods of life. It is also important to address comorbid 
including depression and other mental health concerns. Future compli ca-
of adolescents with PCOS include the potential of endometrial carcinoma, diabetes 
(type 2), infertility, cardiovascular disease, and hyperlipidemia. 
sustained, or unpatterned uterine bleeding not caused by anatomical lesions 
DUB . It is one of the most common menstrual concerns of adolescent females 
noted in about 15 percent of all fema les seeking gynecologic consultation . DUB 
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may lead to anemia (ranging from mild to severe), absence from school (or work), spon-
taneous muscle or joint bleeding, or postsurgical bleeding. ~ Tabs. 17.2 and 17.7 provide 
a list of DUB etiologies that include anovulation, complications of pregnancy, anomalies 
of the reproductive tract, disorders of coagulation, trauma, endocrinopathies, other sys-
temic disorders, trauma, infection (such as PI D), and others (4). ~Tab. 17.2 provides sug-
gested laboratory tests that may be obtained in the evaluation of DUB. 
Tab. 17.7: Causes of abnormal vaginal bleeding. 
Exclude rectal, urethral, and other perineal bleeding 
Vaginal or uterine abnormalities 
• Trauma (coitus, rape, abuse) 
• Foreign body (IUD, tampon, etc.) 
• Infection 
Vaginitis (trichomonas, gonorrhea) 
Cervicitis 
Endometritis (tuberculosis) 
PID 
Sexually transmitted condylomata (HPV) of cervix or vagina 
• Tumor 
Botryoid sarcoma 
Polyps (uterine, cervical) 
Ovarian cyst or tumor (mature teratoma, endometrioma) 
Leiomyomatosis 
Clear cell carcinoma of cervix or vagina (DES) 
Other ovarian malignancy and metastatic malignancy 
• Endometriosis 
• Congenital malformations of uterus 
Complications of pregnancy 
• Threatened or spontaneous abortion 
• Ectopic pregnancy 
• Molar pregnancy 
• Induced abortion 
Coagulopathy 
• Generalized 
• Thrombocytopenia (idiopathic thrombocytopenic purpura; leukemia; lymphoma; aplastic 
anemia, hypersplenism) 
• Platelet dysfunction (von Willebrand's disease; Glanzmann's disease) 
• Clotting disorders (hemophilia; other coagulation factor deficiencies) 
• Uterine production of menstrual anticoagulants 
(Continued) 
Tab. 17.7: Causes of abnormal vaginal bl eeding. (Continued) 
DUB 
• Normal variation 
Midcycle ovulatory bleeding 
Early postmenarcheal anovulation 
Early postmenarchea l estrogen irregularities 
• Chronic anovulation 
• Exogenous steroids 
• Oral contraception 
Midcycle breakthrough bleeding 
• Relative luteal progesterone deficiency 
• Progestogens (oral agents; Norplant; Depo-Provera) 
• Continual estrogens 
• Other drugs 
Danazol 
Spironolactone 
Anticoagulants 
Platelet inhibitors 
Chemotherapy drugs 
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Natural hormones from plant extracts (5-Dehydroepiandrosterone [5-DHEA], Dong Quai, Yam 
Extract) 
• Systemic diseases 
Hyperthyroidism or hypothyroidism 
Adrenal insufficiency 
Cushing's syndrome 
Diabetes mellitus 
Chronic liver disease 
Crohn's disease; ulcerative co litis 
Chronic renal disease 
Systemic lupus erythematosus 
Ovarian fail ure 
• Hyperprolactinemia 
Androgen excess 
Exogenous androgens, PCOS, congenital adrenal hyperplasi as 
Androgen-producing ovarian or adrenal tumor 
Estrogen excess 
Granulosa-theca cell tumor of the ovary 
Other tumors 
(Continued) 
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Tab. 17.7: Causes of abnormal vaginal bleeding. (Continued) 
Hypothalamic 
Emotional stress 
Physical stress, especially exercise 
• Ovulatory 
Short luteal phase 
Prolonged luteal phase (Halban's disease) 
Luteal progesterone insufficiency 
Abbreviations: IUD= Intrauterine device; HPV =human papillomavirus; DES: diethylstilbestrol 
Reprinted, with permission, from (1, p. 547). 
17.2.5 DUB management 
Treatment of DUB consists of treating the symptoms associated as well as the cause. 
The first step, next to identifying the cause, is diagnosing the level of anemia, which 
is based on the classification of mild anemia (hematocrit over 33% or hemoglobin 
over 11 g!dl), moderate anemia (hematocrit 27% to 33% or hemoglobin 9 to 11 g/dl), 
or severe anemia (hematocrit under 27% or hemoglobin under 9 g!dl and/or dropping) 
(15,16). 
17.2.6 Absence of anemia or mild anemia 
Reassurance and monitoring over time is often all that is needed for mild DUB with 
or mild anemia. The patient can be instructed to carefully follow her menstrual 
with a menstrual calendar that can be presented at the office visits for review by her 
nician. If mild anemia is present evaluate dietary inatke and supplement with 300 mg 
ferrous sulfate three times a day. The following box outlines potential adverse 
from iron supplementation. A slow release formulation can decrease some side 
Constipation is a common side effect and therefore, a stool softener is often 
when iron is supplemented. Vitamin Cis often also added to each dose offerrous 
to enhance absorption. 
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In addition to treating the anemia, COCs (also, patch or NuvaRing) can be used for 
to help regulate her menses and help avoid unwanted pregnancy. Depo-medroxy-
progesterone acetate (DMPA) is not typically recommended as it may worsen the men-
strual irregularity and potentially lead to amenorrhea; an intramuscular injection should 
be avoided in those with coagulation disorders. NSAIDs (nonsteroidal anti-inflammatory 
drugs) are helpful in reducing menstrual blood flow by as much as 50 percent via a 
direct effect on the endometrium that balances the vasodilator prostaglandin 12 and 
the potent vasoconstrictor thromboxane A2 (17-19). 
17.2.7 Moderate anemia 
The COC (typically a 30 to 35 meg ethinyl estradiol type) is used to control bleeding in 
patients with DUB marked by moderate anemia. The importance of estrogen is that it 
binds to receptors in the endometrium, provides stabili zation of the endometrial vascu-
lature and stroma, and stimulates specific growth factors . The pill can be provided in 
a dose of two to four times a day until the bleeding is stopped and then gradually 
tapered over 14 to 21 days to allow for withdrawal bleeding. It can be continued at 
a once a day dosage for the next few months or longer if necessary. A longer dosing 
pattern (3-6 months) will also allow correction of the underlying anemia. Higher levels 
of estrogen may cause nausea and therefore, an antiemetic medication can be added to 
alleviate any nausea or emesis that may occur. Iron supplementation can be provided 
as discussed previously. 
An alternative to use of the oral contraceptive is prescription of oral equine estrogen 
(2.5 mg for 21-25 days each month) followed by medroxyprogestone acetate (1 0 mg a 
day) for the last 7 days of the menstrual cycle. The use of progesterone-only agents is 
preferred by some clinicians, as outlined in ~Tab. 17.8. Initially high doses may be 
needed to induce endometrial atrophy and then estrogen can be continued to be pre-
scribed for a number of days to avoid breakthrough bleeding. Some physicians add an 
oral progesterone agent over the last 1 0 days of the menstrual cycle each month to 
avoid unopposed estrogen effects, allow endometrial stabilization and allow organized 
17.8: DUB control with progesterone-only agents. 
Medroxy-progesterone acetate (MPA) 
1. 10 mg every 4 hours, then QID - 4 days, TID - 3 days, BID - 14 days) 
2. High dose may be necessary: 40-80 mg per day or 100 mg Depo 1M/day 
Norethindrone acetate 
1. 1 0 mg eve ry 4 hours, then every 6-8 hours to 12 hours; taper as bleeding decreases 
2. May stay on 5 mg every 12 hours for months if necessary with l if necessary (as teen with 
a pl asti c anemia and low platelet count) 
3. 0.35 mg OD- BID for breakthrough bleeding 
Megestrol acetate (80 mg BID may be needed) 
four times daily; TID, three times daily; BID, twice daily; OD, once da ily. 
1\11'""'"""'" with permission from (4, p. 60). 
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endometrial sloughing. Concerns about using cyclic oral progestin therapy include 
potential bloating, acne vulgaris, increased appetite-induced weight gain, and reduced 
contraceptive effect. 
Severe anemia 
Intravenous fluids and blood products may be necessary in this situation along with 
high dose estrogen, such as use of intravenous conjugated equine estrogens (25 mg ini-
ti ally and repeat dose every 4-6 hours for up to 4 doses) (4, 17,18,19). The high dose 
estrogen induces rapid hemostasi s because of increased production of fibrinogen, in-
creased activity of Factors V and IX, and increased aggregation of platelets. Use of 
such high dose estrogen may increase thromoembolism risks. An antiemetic, again, 
is added to control the potential nausea and emesis. A progesterone agent is added to 
induce controlled withdrawal bleeding from the endometrium. Some clincians prefer to 
use an oral contraceptive dosing pattern (see the following box) to avoid use of intravenous 
estrogen. 
17.2.8 Management of DUB due to coagulation disorders 
Control of DUB in adolescent females with coagulation disorders can be compl ex and 
consultation with experts in hematology is recommended (4) . The cornerstone of 
bleed ing control is appropriate factor replacement therapy with additional 
logica l agents that include intranasal DDAVP (1-deamino-8-D-arginine 
(Desmopressin acetate), antifibrinolytics (epsilonamino caproic acid [Amicar] or 
nexamic acid (Cyklokapron), COCs, and/or levonorgestrel-releasing IUD (Mirena 
see ~Tab . 17.9). COCs raise Factor VIII activity (FVIII:Ac) in hemophilia carriers. In 
patients with von Willebrand's disease, estrogen rai ses Factor Vlll/vWF-ristocetin co-
factor activity, and partially corrects prolonged bleeding time. If there is a history 
deep vein thrombosis, and estrogen is used to control severe DUB, coumadin 
be added as adjunctive therapy. 
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Tab. 17.9: Effects and benefits of levonorgestrel IUD. 
A. Contraceptive effects 
• Prevents fertilization 
• Interferes with ovum development 
• Interferes with sperm movement and ability to penetrate ovum 
• Inhibits sperm survival 
• Helps prevent egg release 
• Thickens cervical mucus 
B. Benefits 
• Effective contraception for 5 yea rs 
• Eventual reduction in menstrual flow 
• OK for those with coagulation disorders 
• Up to a 90% reduction in bleeding 
• 20%-50% with no menses after one year 
• Good for those with mental retardation/developmental disorders 
• Frequent amenorrhea 
• Decreased dysmenorrheal 
• Decreased premenstrual syndrome 
• Very low rates of infectious complications 
Modified with permission from (4, p. 64) . 
17.2.9 Other DUB management options 
There are other treatment options commonly used in adults, but less commonly in ado-
lescents with severe and/or persistent DUB. These potential management strategies 
include danocri ne, GnRH agonists, and surgica l options, such as dilation and curettage, 
and hysterectomy. Danazol (Danocrine) is a synthetic hormonal agent prescribed to 
manage endometriosis, breast cysts, and severe DUB in adult females. Its benefits in-
cludes estrogen suppress ion and cessation of menstruation (4). GnRh agonists (i .e. 
buserelin, leuprolide [Lupron Depo], and nafarelin [Synarel]) stop menstruation, but 
there is limited research data on their use in adolescent femal es. 
17.3 Dysmenorrhea 
Dysmenorrhea is typically divided into primary and secondary dysmenorrhea. Primary 
dysmenorrhea refers to menstrual pain with no underlying pelvic pathology; secondary 
dysmenorrhea refers to pelvic (menstrual) pain resulting from anatomic and/or pelvic 
pathology. ~Tab. 17.2 outlines the definition and differential diagnosis for dysmenor-
rhea. Primary dysmenorrhea is often classified as mild, moderate, and severe. Mild dys-
menorrhea does not interfere with normal daily activi ties and only minimal analgesic 
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support is needed. With moderate dysmenorrhea, there is some reduction in activities 
and the use of analgesics is necessary. Severe dysmenorrhea implies that regular activities 
do not occur during the active phase of the symptoms and analgesics are usually not ben-
eficial. Approximately two-thirds of ovulating females report some menstrual discomfort 
for 1 to 3 days of most ovulatory cycles with about half having mild dysmenorrhea, 
one-third with moderate cramping, and about 14 percent with severe dysmenorrhea (4). 
Primary dysmenorrhea is the most common medical reason for school or work 
absence and it has an increasing incidence from the early adolescent years to young 
adulthood and first pregnancy (20,21 ). Primary dysmenorrhea often starts 6 to 12 
months postmenarche, though it may not been seen until the third year postmenarche. 
The pain associated with menstruation may start before the initiation of menstrual flow 
or once menstrual flow starts. The symptoms associated with dysmenorrhea can vary 
patient to patient and are illustrated in the box, "Features Associated with Primary Dys-
menorrhea." When a patient presents with dysmenorrhea, the first step is to differenti-
ate primary from secondary dysmenorrhea (see~ Tab. 17.2). It is also helpful to identify 
factors which can alleviate or aggravate the pain (see the box, "Factors That Improve or 
Worsen Primary Dysmenorrhea"). 
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17.3.1 Etiology 
The etiology of the menstrual cramping in primary dysmenorrhea is due to the condi-
tions set after ovulation occurs with the increase and decrease in progesterone levels 
that induce release of prostaglandins that stimulate a rise in uterine contractions and 
endometrial nerve endings' irritation (2 1-23). The result is variable menstrual cramping 
and pain due to a rise in myometrial resting tone, increased frequency and amplitude of 
contractions, and a rise in dysrhythmic contractions. Those with primary dysmenorrhea 
have higher levels of circulating prostaglandins during menstruation in contrast to those 
without such cramping. In addition, research suggests that those with primary dysme-
norrhea have heightened sensitivity to prostagl andins in the circulation and also higher 
vasopressin levels that can lead to increased uterine contractions and increased 
menstrual pain. 
17.3.2 Primary dysmenorrhea management 
NSAIDs 
The initial pharmacological management for those with primary dysmenorrhea is 
NSAIDs that includes nonselective (COX-1 and COX-2 inhibitors) (see the following 
box) and selective or COX-2 inhibitors. Efficacy in the management of primary dysme-
norrhea includes the suppression of cyclic endoperoxide synthetase at the cyclooxy-
genase level. In general, there is often no difference in effi cacy and choice of 
therapeutic agents is determined by cost, convenience, adverse effects, and patient 
preference. It is thought that enolic acids (i.e. oxicams) not only may not be as effective 
for primary dysmenorrhea, but also has many more side effects. 
320 I 17 Menstrual disorders in the ado lescent female 
The NSAIDs with the highest benefit with lowest adverse effects are the 
acids: ibuprofen, naproxen, naproxen sodium, and ketoprofen (see the previous 
"NSAIDs," and ~Tab. 17.10). Propionic acids are FDA approved for the treatment 
primary dysmenorrhea and dosages are listed in ~Tab. 17.10. Side effects 
headache, gastrointestinal upset, heartburn, indigestion, rash, and dizziness. 
sodium has a long half-life allowing for twice-a-day dosing. Ketoprofen has 
kinin action, provides stabilization of lyosomal membranes, and inhibits nrr\ct~,aJ~m 
as well as leukotriene synthesis. 
Several propionic acids are available as over-the-counter agents and higher doses 
available with prescription. As discussed previously, it is helpful for the patient to 
a calendar of her menstrual cycles so that she knows when her menses should 
and can initiate pharmacological therapy. Medication can be continued for two 
four days as needed for pain and reduction of blood loss. Partial to near 
pain improvement is noted in about 80 percent of those with primary 
Failure of benefit may be due to absence of prostaglandin synthetase inhibitors 
the 5-lipooxygenase pathway that allows continued production of leukotrienes. It is 
important to remember that if there is no improvement in pain, secondary 
should be considered. 
Salicyli c ac id esters (i.e. aspirin) is not efficacious in treatment of dysmenorrhea 
it has limited anti-inflammatory effects on the endometrium. Indomethacin 
effective agent but has significant potential side effects including renal 
prolonged vaginal bleeding, headaches, gastrointestinal ulcers and gastric 
Fenamic acids (mefenamic acid (~Tab. 17.1 0), meclofenamate) have a rapid 
of action and can reduce bleeding in pati ents with menorrhagia. These 
act by blocki ng myometrial receptor sites for synthesized prostaglandins as well 
lead to inhibition of 5-lipooxygenase activi ty (with resultant leukotriene 
suppression) . 
Tab. 17.10: NSAIDs for the treatment of primary dysmenorrhea. 
Drug Initial Dose Maintenance Dose Max imum Dose/24 
(mg) hours (mg) 
Ibuprofen• 400 400 mg q 4 hours 3,200 
Ketoprofen 25-50 25-50 mg q 6-8 hours 300 
Naproxen• 550 275 mg q 6-8 hours or 550 mg q 1,375 
sodium 500 12 hours 1,250 
Naproxen 500 250 mg q 6- 8 hours or 500 mg q Not established 
Mefenamic acid 12 hours 
250 q 4 hours 
"Available as over-the-counter drugs in the United States: ibuproren, 200 mg tablets; 
sodium, 220 mg tablets. 
*Used with perimission from (3, p. 387) . 
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Oral contraceptives 
COCs may be used for primary dysmenorrhea if NSAIDS are not beneficial, as ad-
junctive management to NSAIDs, and also as first line therapy if the patient is seek-
ing contraception. COCs prevent ovulation and this blocks the development of the 
postovulatory rise in prostaglandin levels because of the ovulation-induced corpus 
luteum. Blood flow is often reduced and menstrual cramps are lessened in up to 95 
percent of females with primary dysmenorrhea on COCs. Other forms of hormonal 
contraception are also efficacious, such as the patch, transvaginal, injectab le, or 
implantable (subdermal) methods. If a combination of NSAIDs and hormonal con-
traceptives are not helpful to a considerab le extent, consider that the patient may 
have secondary versus primary dysmenorrhea (see .,.Tab. 17.2). Other management 
options for treatment of primary dysmenorrhea are listed in the following box. 
17.3.3 Secondary dysmenorrhea 
There are many diagnoses in the differential for secondary dysmenorrhea including en-
dometriosis, PID, reproductive tract anomalies (Mullerian defects), and others (see 
..,.. Tab. 17.2). A careful medical history can often provide clues that an organic lesion 
is the cause of the dysmenorrhea. For example, the pain may begin at menarche or 
three years (or more) after the onset of menses. There may be atypical pain, pain asso-
ciated with DUB or changing menstrual patterns, pain that is not relieved with NSAIDS 
and hormonal contraception, and pain that develops after pelvic surgery. The following 
box outlines questions to ask in the medical history to help delineate between primary 
and secondary dysmenorrhea. A careful examination and selective laboratory testing 
are necessary to identify the underlying cause(..,.. Tab. 17.2). Management is dependent 
on the underlying etiology (4). Endometriosis is one of the most common causes of 
secondary dysmenorrhea. 
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17.4 Endometriosis 
The development of endometrial stroma and glands outside of the uterus defines the 
feature of endometriosis. Though more commonly associated with adult females, it 
been seen in half or more of adolescent females with chronic pelvic pain. Reflux of 
dometrial tissue from oviducts during menses may occur in a process termed 
menstruation; other mechanisms include the development of endometrial tissue 
small cysts found over the pelvis, such as uterine surface, ovaries, pelvic ligaments, 
the peritoneum (coelomic metaplasia). The precise underlying mechanisms are 
and thus various theories are proposed to explain why endometrial tissues are not 
from nonuterine locations; these theories include immunologic deficiencies, 
vascular metastases, and genetic factors. Recent research focuses on the major role 
prostaglandin E2 (24). Pain arises in endometriosis because of swelling of 
cysts during menses, pelvic adhesion-induced pain, or stimulation of various 
nerve endings. 
17 .4.1 Symptomatology 
Features consistent with endometriosis include severe dysmenorrhea unresponsive 
analgesics or hormonal medication, chronic pelvic pain, and infertility. A variety 
pain patterns exist depending on the location of the endometriotic lesions. There 
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no association between the number of lesions and the pain intensity. Abnormal 
menstrual bleeding can be seen along with various other symptoms, including clinical 
hematuria, suprapubic pain, dyspareunia, and/or dysuria. Variable gastrointestinal 
symptomatology may also be present arid include pain with defecation (dyschezia), 
rectal pressure, and urgency. Endometriosis can also present with large ovarian 
endometriomas and adnexal masses. 
17.4.2 Diagnosis 
Identifying the pattern and location of pain can help in differentiating the etiology . 
..,. Tab. 17.11 outlines a diagnostic approach to adolescent females with pelvic pain . 
..,.Tab. 17.12 outlines a diagnostic plan for pelvic masses. A pelvic examination in a 
patient with endometriosis may be normal or reveal various abnormalities, such as pel-
vic tenderness, fixed (immobile) uterine, thickened broad ligaments, and/or unpredict-
able nodularity with or without tenderness. Various pelvic cysts or an adnexal mass 
may be noted by ultrasonography while a pelvic MRI may reveal genital reproductive 
tract anomalies. Females with endometriosis may have an increased CA-125 (cell sur-
face antigen). Although this test has a low sensitivity and is not a cost-efficient screening 
test, levels of this antigen can be used to follow clinical response to treatment. The gold 
standard of diagnosing endometriosis is laparoscopy with biopsy and this should 
be performed in adolescent females with chronic pelvic pain of unknown cause not 
responding to NSAIDs and hormonal medication. Endometriotic lesions can appear 
differently in adolescent versus adult females (4). 
Tab. 17.11: Differential diagnostic approach to pelvis pain. 
Characteristics of Pain 
Cyclical, normal bleeding 
Acute, irregular bleeding 
Likely Diagnosis Confirmatory Investigations 
Midline Location 
Physiological 
dysmenorrhea 
Endometriosis 
Endometriosis 
Threatened or septi c 
abortion 
History; pelvic examination (normal) 
Pelvic examination; sonography; 
laparoscopy 
Pelvic examination, cultures; CBC; 
sedimentation rate 
History; pelvic examination; pregnancy 
test 
Unrelated to menses, urinary Cystitis History; urinalys is, urine culture 
symptoms a 
Cyclical, normal bleeding 
Normal uterine 
pregnancy 
History; pregnancy test 
Lateral Location 
Mittelschmerz History (timing, nature); pelvic 
examination (normal) 
(Continued) 
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Tab. 17.11: Differential diagnostic approach to pelvis pain. (Continued) 
Characteristics of Pain Likely Diagnosis 
Endometriosis 
Acute, postmenstrual Salpingitis or PID 
Acute, abnormal bleeding Ectopic pregnancy 
Unrelated to menses, acute Appendicitis 
Unrelated to menses, 
chronic 
Ureteral co lic 
Constipation 
Pelvic osteomyelitis 
Psychogenic 
Abbreviation: CBC = complete blood count. 
Confirmatory Investigations 
Pelvic examination; sonography; 
laparoscopy 
History; pelvic examination, cultures; 
CBC, sed rate; laparoscopy 
History; pelvic examination, pregnancy 
test 
History; physical examination; CBC; 
radiography 
History; urinalysis; radiography 
History; rectal examination 
Physical examination; radiography; 
gallium scan 
History; exclusion of others; nn,r••ncnr. 
evaluation 
aDysuria and urinary frequency may be associated with infection, pregnancy, and 
factors. 
Reprinted, with permission, from (1, p. 547). 
Tab. 17.12: Differential diagnosis of pelvic masses. 
Characteri stic of Mass Differential Diagnosis 
Midline Location 
With amenorrhea or 
abnormal menses 
With normal menses 
Lateral Location 
With amenorrhea or 
abnormal menses 
Pregnancy 
Hematocolpos, 
Hematometra 
Uterine sarcoma (rare) 
Bladder 
Functioning ovarian cyst 
(Tab. 17.2) Ovarian tumor 
Confirmatory History, Findings, 
and Procedure 
History of sexual activity; positive pelvic 
examination 
History of no menses, cycl ic pelvic 
perineal examination reveals 
hymen, vaginal stenosis 
Negative pregnancy test; uterine 
enlargement; sonography CT; tissue 
diagnosis 
History of acute retention; findings of 
herpetic or other les ions precipitating 
retention; catheteri zation 
History of menstrual irregu larity; 
test; unilateral mass; 
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Tab. 17.12: Differential diagnosis of pelvic masses. (Continued) 
Characteristic of Mass Differential Diagnosis 
PCOS (Tab. 17.2) 
With normal menses Ectopic pregnancy 
(Tab. 17.2) 
Tuboovarian abscess 
(Tab. 17.2) 
Nonfunctioning ovarian 
cyst (Tab. 17.2) 
Appendiceal abscess 
Fecal impaction 
Abbreviation: CT =computed tomography. 
Reprinted, with permission, from (1, p. 559). 
17.4.3 Management of endometriosis 
Confirmatory History, Findings, 
and Procedure 
laboratory evidence of hormonal 
abnormalities; sonography, laparoscopy, 
tissue diagnosis 
As above with bilateral ovarian 
enlargement 
History of sexual activity; pregnancy test 
may or may not be positive; sonography; 
may or may not have pain or tenderness; 
may present as acute emergency 
History and findings compatible with PID; 
sonography, laparoscopy 
History of pain or asymptomatic; unilateral 
mass; may be very large; sonography, 
laparoscopy, tissue diagnosis 
History of appendicitis (or acute abnormal 
condition); positive rectal or abdominal 
examination; may be difficult to 
distinguish from PID; sonography, 
laparotomy 
History of constipation; positive rectal or 
abdominal examination; abdominal 
roentgenograms 
Endometriosis is a complex and perplexing condition that should be managed in consul-
tation with a gynecologist. There are many treatment options and these are listed in the 
following box. NSAIDs (..,..Tab. 17.1 0) are usually not beneficial in females with endome-
triosis while hormonal medications may be useful in reducing (even removing) nonuter-
ine endometriotic tissue. Clinicians can use oral contraceptives, patch contraception, 
transvaginal hormonal contraceptives, DMPA (150 mg intramuscularly every 3 months), 
or oral MPA (30-50 mg once a day). Adverse effects of progestins include irregular bleed-
ing, bloating, weight gain, and others. If COCs are contraindicated (see contraception 
chapter [chapter 19]), one may use a progestin-dominant oral contraceptive. 
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Danazol, a steroidal androgen can be used which suppresses cyclic changes and 
eventually causes atrophy of the endometriotic sites. Careful observation of potential 
adverse effects is important and these may include including fetal androgenisation, 
thrombotic events, elevated liver function tests, hyperlipidemia, acne vulgaris, weight 
gain, edema, and others. 
Gonadotropin-releasing hormone agonists (leuprolide acetate or nafarelin acetate) 
can also be prescribed by themselves or in combined with estrogen. The addition of 
estrogen can help prevent the reversible state of menopause with amenorrhea, hot 
flashes, vaginal dryness, and loss of bone mass. If these agonists are used, they are usu-
ally stopped after 6 months unless estrogen is added to permit an additional 6 months 
use due to bone loss associated with GnRH agonist. 
Aromatase inhibitors (anasazole) is used to treat postmenapausal breast cancer but 
can be used for adults with endometriosis; it may be combined with oral contraceptives 
or GnRh. This may be an option for women who have not had success with other 
treatment or unable to use other treatment modalities. 
Surgical management is also useful for many with endometriosis as noted in the pre-
vious box, "Treatment Options for Endometriosis," and hormonal management can be 
continued after surgery to control the development of endometriosis that may occur 
after surgical treatment. Preservation of fertility is also the goal of any surgical procedure 
in the treatment of endometriosis. 
17.5 PMS 
PMS identifies various symptoms (see .,.. Tab. 17.13) that typically initiate during the 
latter luteal phase just before the onset of the menstrual flow and tend to resolve 
with the initiation of menstrual flow(.,.. Tab. 17.2). Most reproductive females report 
PMS features and up to 8 percent note severe emotional symptoms (i.e. anxiety, 
depression, failure to perform daily activities) that meet the American Psychiatric As-
sociation's criteria for PMDD (25,26). Various theories are proposed for PMS, though 
the precise causes are not known at this time (see the following box, "Proposed 
Theories for PMS"). 
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Tab. 17.13: PMS symptomatology. 
Emotional Features 
• Anecdotal reports of violence and suicide 
• Anger 
• Anxiety 
• Concentration difficulties 
• Crying 
• Decreased libido 
• Depression 
• Feelings of being out of control or overwhelmed 
• Lethargy 
• Mood swings 
• Withdrawal from usual activities 
Physical Features 
• Acne 
• Anorexia 
• Bloating 
• Breast tenderness or swelling 
• Constipation 
• Diarrhea 
• Edema 
• Facial puffiness 
• Fatigue 
• Headache 
• Increased appetite 
• Lower abdominal or pelvic pain 
• Pain: joints or muscles 
• Swelling of hands 
• Swelling of feet 
• Weight gain 
Used with permission from (3, pp. 388-89) . 
A careful evaluation is necessary to exclude PMS from such conditions as chronic 
fatigue syndrome, anemia, diabetes mellitus, hypothyrodism, collagen vascular disor-
ders, and others. Adding to the confusion are the various conditions that may be 
worsened by menstruation; these include migraine headaches, erythema multiforme, 
acute intermittent porphyria, rheumatoid arthritis, recurrent anaphylaxis, and the three 
"periodic" conditions - periodic fever, paralysis, and hypersomnia. 
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17.5.1 Management of PMS 
Various supportive measures are typically recommended for PMS symptoms including 
regular exercise, healthy sleep-wake cycles, regular hot baths, reduced salt intake, re-
duced intake of caffeinated beverages (often high in adolescents), improved nutrition 
(with less sugar), abstinence from alcohol, and reduction in excessive stress. NSAIDs 
may improve breast or pelvic pain noted in some with PMS, while diuretics (such as 
spironolactone or hydrochlorothiazide) may relieve symptoms due to PMS weight 
gain or edema; abuse of diuretics, however, may lead to increased weight gain from 
increased edema. 
Measures often suggested but without supportive research include herbal or vitamin 
supplementation . Such measures attempted, but without specific research to verify 
benefit, include oral contraceptives, progesterone, thyroid hormone supplementation, 
lithium, evening primrose oil, atenolol, prostaglandin inhibitors, vitamin E or B6 
supplementation, and supplementation with calcium or magnesium. 
Management of symptomatic anxiety or depression (or mental health disorders) is 
important. PMS emotional features (~Tab. 17.12) may show some improvement with 
the judicious use of selective serotonin reuptake inhibitors (SSRis), such as sertraline 
(50 mg daily), fluoxetine (20 mg daily), or paroxetine (20 mg daily). See the chapter 
on mood disorders (chapter 12) for review of the uses and potential side effects of 
SSRls, including the FDA black box warning on increased suicidality in adolescence. 
Those with excessive symptoms of anxiety may benefit from prescription of anxiolytics 
such as alprazolam or buspirone. Some clinicians have used tricyclic antidepressants 
(such as clomipramine), though great care should be exercised in prescribing tri cyclic 
antidepressants to adolescents due to the many side effects (27). 
Measures used for adults with severe PMS include gonadotropin-releasing hor-
mone (GnRH) agonists (such as leuprolide [Lupron] and buserelin [Suprefact]). 
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These agents produce a medical oophorectomy by suppression of gonadotropin 
release with resultant prevention of ovulation and ovarian hormone production. 
Adult females with severe mastalgia as part of their PMS have been prescribed 
bromocriptine, a dopamine-receptor agonist. 
17.6 Summary 
Menstrual disorders are common disorders in the adolescent female. This chapter 
reviews basic concepts of menstrual disorders in adolescents beginning with an over-
view of menstrual physiology followed by consideration of various abnormal men-
strual patterns: amenorrhea (primary and secondary), DUB, dysmenorrhea (primary 
and secondary), and premenstrual syndrome. 
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